This was a non-interventional retrospective study. Data from patients who were diagnosed with myelofibrosis (MF) (primary MF, post-polycythemia vera MF \& post-essential thrombocythemia MF) and treated with ruxolitinib for at least 3 months collectively were collected. The baseline visit was the visit that the patient started ruxolitinib treatment. Data was collected between January 01, 2015 and December 31, 2022. The main baseline clinical and laboratory data of the cohort with at least 3 months of ruxolitinib treatment was documented in order to identify real life patient data in Turkey. All the data was transferred to a clinical report form (CRF), then to the Statistical Package for the Social Sciences (SPSS) software in an anonymous fashion. The source documents were secured for quality control of the data. The quality control of the data was controlled by an unbiased data entry coordinator.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Age
Timeframe: Baseline
Number of Patients by Gender
Timeframe: Baseline
Number of Patients by Clinical Characteristic Category
Timeframe: Baseline
Time From Diagnosis to Initiation of Ruxolitinib
Timeframe: Baseline
Number of Patients by DIPSS+ Risk Stratification
Timeframe: Baseline, Month 12
Percentage of Patients With Blood Transfusions
Timeframe: Baseline, Month 3, 6, and 12
Percentage of Patients With Splenomegaly
Timeframe: Baseline, Month 3, 6, and 12
Change From Baseline in Percentage of Patients With Splenomegaly
Timeframe: Baseline, Month 12
Percentage of Patients Categorized by Spleen Size
Timeframe: Baseline, Month 3, 6, and 12
Hemoglobin Levels
Timeframe: Baseline, Month 3, 6, and 12
Hematocrit Levels
Timeframe: Baseline, Month 3, 6, and 12
White Blood Cell (Leukocyte) Count
Timeframe: Baseline, Month 3, 6, and 12
Platelet Count
Timeframe: Baseline, Month 3, 6, and 12
Lactate Dehydrogenase (LDH) Levels
Timeframe: Baseline, Month 3, 6, and 12